Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

KASL clinical practice guidelines for management of chronic hepatitis B

Clinical and Molecular Hepatology (2019) Vol. 25, Iss. 2, pp. 93-159
Open Access | Times Cited: 190

Showing 1-25 of 190 citing articles:

Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus–Related Hepatocellular Carcinoma After Surgical Resection
Jonggi Choi, Chanyoung Jo, Young‐Suk Lim
Hepatology (2020) Vol. 73, Iss. 2, pp. 661-673
Closed Access | Times Cited: 101
Serum Exosomal MicroRNA, miR-10b-5p, as a Potential Diagnostic Biomarker for Early-Stage Hepatocellular Carcinoma
Hyo Jung Cho, Jung Woo Eun, Geum Ok Baek, et al.
Journal of Clinical Medicine (2020) Vol. 9, Iss. 1, pp. 281-281
Open Access | Times Cited: 100
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients
Gi‐Ae Kim, Seungbong Han, Gwang Hyeon Choi, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 51, Iss. 11, pp. 1169-1179
Closed Access | Times Cited: 74
Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immune‐tolerant phase
Han Ah Lee, Hyun Woong Lee, In Hee Kim, et al.
Alimentary Pharmacology & Therapeutics (2020) Vol. 52, Iss. 1, pp. 196-204
Closed Access | Times Cited: 57
Association of Metabolic Risk Factors With Risks of Cancer and All‐Cause Mortality in Patients With Chronic Hepatitis B
Yun Bin Lee, Hyemi Moon, Jeong‐Hoon Lee, et al.
Hepatology (2020) Vol. 73, Iss. 6, pp. 2266-2277
Closed Access | Times Cited: 56
Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients
Daniel E. Dulek, Robert C. Fuhlbrigge, Alison C. Tribble, et al.
Journal of the Pediatric Infectious Diseases Society (2020) Vol. 9, Iss. 6, pp. 716-737
Open Access | Times Cited: 53
Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus
Sun Woong Kim, Jun Sik Yoon, Minjong Lee, et al.
Clinical and Molecular Hepatology (2021) Vol. 28, Iss. 1, pp. 17-30
Open Access | Times Cited: 48
Risk Factors and Prevention of Viral Hepatitis-Related Hepatocellular Carcinoma
Xinhe Zhang, Lin Guan, Haoyu Tian, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 41
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis
Heejoon Jang, Yun Bin Lee, Hyemi Moon, et al.
Hepatology (2022) Vol. 76, Iss. 2, pp. 492-501
Closed Access | Times Cited: 37
Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B
Won‐Mook Choi, Gi‐Ae Kim, Jonggi Choi, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 10
Open Access | Times Cited: 34
A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance
Hyun Yang, Si Hyun Bae, Heechul Nam, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 3, pp. 632-641
Closed Access | Times Cited: 32
Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis
Young‐Suk Lim, Sang Hoon Ahn, Jae‐Jun Shim, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 3, pp. 519-528
Closed Access | Times Cited: 30
Hepatitis B Virus Treatment and Hepatocellular Carcinoma: Controversies and Approaches to Consensus
Soo Ki Kim, Takako Fujii, Soo Ryang Kim, et al.
Liver Cancer (2022) Vol. 11, Iss. 6, pp. 497-510
Open Access | Times Cited: 29
Air pollution as a potential a risk factor for hepatocellular carcinoma in Taiwanese patients after adjusting for chronic viral hepatitis
Tyng‐Yuan Jang, Chi-Chang Ho, Chih‐Da Wu, et al.
Journal of the Chinese Medical Association (2024) Vol. 87, Iss. 3, pp. 287-291
Open Access | Times Cited: 5
Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B
Hye‐Lin Kim, Gi‐Ae Kim, Jae‐A Park, et al.
Gut (2020) Vol. 70, Iss. 11, pp. 2172-2182
Closed Access | Times Cited: 40
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data
Young‐Suk Lim, Wai‐Kay Seto, Masayuki Kurosaki, et al.
Alimentary Pharmacology & Therapeutics (2022) Vol. 55, Iss. 8, pp. 921-943
Open Access | Times Cited: 22
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis
Na Ryung Choi, Ju Yeon Kim, Ji Hoon Hong, et al.
BMC Gastroenterology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 22
Prevention and management of infectious complications in patients with chronic lymphocytic leukemia (CLL) treated with BTK and BCL-2 inhibitors, focus on current guidelines
Małgorzata Mikulska, Chiara Oltolini, Emanuela Zappulo, et al.
Blood Reviews (2024) Vol. 65, pp. 101180-101180
Open Access | Times Cited: 4
Switching to Besifovir in Patients with Chronic Hepatitis B Receiving Tenofovir Disoproxil Fumarate: A Randomized Trial
Hyung Joon Yim, Yeon Seok Seo, Jihoon T. Kim, et al.
Clinical and Molecular Hepatology (2025)
Open Access
Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
Tyng‐Yuan Jang, Yuting Zeng, Po‐Cheng Liang, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access
Evaluating the predictive value of clinical models for HBV-related hepatocellular carcinoma: A meta-analysis
Long Huang, Lu-Huai Feng, Lu Yang, et al.
Frontiers in Medicine (2025) Vol. 12
Open Access
Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B: A Multicenter Study
Seung Up Kim, Yeon Seok Seo, Han Ah Lee, et al.
Cancer Epidemiology Biomarkers & Prevention (2020) Vol. 29, Iss. 4, pp. 832-837
Closed Access | Times Cited: 33
Tenofovir disoproxil fumarate directly ameliorates liver fibrosis by inducing hepatic stellate cell apoptosis via downregulation of PI3K/Akt/mTOR signaling pathway
Sung Won Lee, Sung Min Kim, Wonhee Hur, et al.
PLoS ONE (2021) Vol. 16, Iss. 12, pp. e0261067-e0261067
Open Access | Times Cited: 30
The efficacies of entecavir and tenofovir in terms of enhancing prognosis after curative treatment of hepatitis B virus–related hepatocellular carcinoma
Ji Hyun Lee, Beom Kyung Kim, Soo Young Park, et al.
European Journal of Internal Medicine (2021) Vol. 89, pp. 48-55
Closed Access | Times Cited: 29
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection
Jung Hwan Yu, Soon Gu Cho, Young‐Joo Jin, et al.
Clinical and Molecular Hepatology (2021) Vol. 28, Iss. 3, pp. 351-361
Open Access | Times Cited: 28
Page 1 - Next Page

Scroll to top